Indeed, initial studies using sub-cutaneous xenografts of RSPO-fusion human CRCs, highlighted the potential of PORCN inhibitors26 or direct RSPO3 neutralizing antibodies31 for treatment of these tumours. The gene discussed is RSPO3; the disease is neoplasm.